New combination keeps inflammation down

Article

A new fixed combination of dexamethasone and netilmicin offers an effective and safe way to control ocular inflammation after cataract surgery.

A new fixed combination of dexamethasone and netilmicin offers an effective and safe way to control ocular inflammation after cataract surgery, according to results of a study published in the January issue of Eye.

S. Russo and colleagues from the Medical department at SIFI S.p.A, Italy and the Military Hospital, Romania, enrolled 223 patients to receive either I mg/ml dexamethasone plus 3 mg/ml netilmicin (n=148) or 1 mg/ml dexamethasone plus 3 mg/ml tobramycin (Tobradex) (n=75), four times a day for seven days after cataract surgery. Efficacy and safety were analysed one and seven days postoperatively, in addition to a follow-up visit 142 days postoperatively. The extent of anterior chamber inflammation, measured by slit-lamp according to a standard scoring system, was used as the primary efficacy parameter.

At seven days both fixed combinations were equally effective in reducing inflammation and the dexamethasone/netilmicin combination demonstrated a good safety profile, with no evidence of poor local tolerance or adverse reactions.

It was concluded that this new fixed combination is both effective and safe as a treatment for ocular inflammation following cataract surgery.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.